Nutriband Inc. (NTRB)

US — Healthcare Sector
Peers: QNRX  LGVN  RNXT  VRAX    INDP  RZLT  TPST  CMRA  FBRX  ANEB  HCWB  ELYM  MOLN  MNOV  CSBR  CYT 

Automate Your Wheel Strategy on NTRB

With Tiblio's Option Bot, you can configure your own wheel strategy including NTRB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NTRB
  • Rev/Share 0.1932
  • Book/Share 0.5805
  • PB 11.1284
  • Debt/Equity 0.029
  • CurrentRatio 4.8779
  • ROIC -1.5547

 

  • MktCap 72056132.0
  • FreeCF/Share -0.4261
  • PFCF -15.2706
  • PE -6.8249
  • Debt/Assets 0.0249
  • DivYield 0
  • ROE -0.9643

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation NTRB Noble Capital Markets -- Outperform -- $13 Jan. 22, 2025

News

Nutriband Inc. (NTRB) Reports Q1 Loss, Misses Revenue Estimates
NTRB
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Negative

Nutriband Inc. (NTRB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.21 per share a year ago.

Read More
image for news Nutriband Inc. (NTRB) Reports Q1 Loss, Misses Revenue Estimates
Nutriband CEO Publishes Letter to Shareholders
NTRB, NTRBW
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral

ORLANDO, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and milestones through 2024 and the potential outlook for 2025.

Read More
image for news Nutriband CEO Publishes Letter to Shareholders
Nutriband Signs Partnership Agreement with Charlotte FC
NTRB, NTRBW
Published: April 04, 2025 by: GlobeNewsWire
Sentiment: Neutral

ORLANDO, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the “Company”)(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it has signed an Associate Partnership agreement with Charlotte FC.

Read More
image for news Nutriband Signs Partnership Agreement with Charlotte FC
Nutriband and Kindeva Drug Delivery Formalize Exclusive Development Partnership for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch
NTRB, NTRBW
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral

Nutriband and Kindeva formalize exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments Nutriband is partnering with Kindeva Drug Delivery to develop Aversa™ Fentanyl which combines Nutriband's Aversa™ abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch. ORLANDO, Fla.

Read More
image for news Nutriband and Kindeva Drug Delivery Formalize Exclusive Development Partnership for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch

About Nutriband Inc. (NTRB)

  • IPO Date 2021-10-01
  • Website https://nutriband.com
  • Industry Biotechnology
  • CEO Mr. Gareth Sheridan
  • Employees 13

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.